

NCI SBIR AND YOUR STATE:

WISCONSIN



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$18 million** in funding across **19 Phase II SBIR/STTR grants** to small businesses in Wisconsin. The following economic impact estimates quantify the program's contributions to the state's economy:



\$306.5M

IN TOTAL DIRECT SALES



\$785M

IN TOTAL ECONOMIC IMPACT



4.3K

JOBS CREATED



\$30.4M

IN STATE & LOCAL TAXES COLLECTED



10

COMPANIES WITH SALES

**These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in Wisconsin: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$53.1M in funding across all grants to oncology-focused small businesses in the state.*

Success stories include:

VOXIMETRY, INC.

Leveraging SBIR funding, Voximetry developed the Torch® radio pharmaceutical therapy (RPT) assessment software that analyzes patients' nuclear medicine scans to develop a personalized dose assessment. It received FDA approval in November 2022.

ONLUME, LLC

OnLume developed its fluorescence guided surgery (FGS) system with SBIR funding to assess vasculature and reduce breast cancer-related morbidities. FDA-approved in January 2020, OnLume has raised more than \$17 million in venture financing and equity offerings to date.

The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to ncisbir@mail.nih.gov.